Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Q3 Revenue Up 8 Percent; Sales of Genomic, Proteomic Tools Strong

NEW YORK, Oct. 29 (GenomeWeb News) - Beckman today reported sales of $581 million for the third quarter, up over $535 million one year ago.

 

The company's Biomedical Research Division, which sells the GenomeLab and ProteomeLab instruments, increased by 5 percent year over year. Clinical Diagnostics, by comparison, was up 10 percent.

 

R&D spending for the period increased to $51.5 million from $46.5 million. Net earnings for the quarter jumped to $57 million, or $.93 per basic earnings per share, from $40 million, or $.65 per basic earnings per share, for the same quarter in 2003.

 

The company reported cash and cash equivalents of $31 million on hand as of Sept. 30.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.